Submitted by comunicaciones on Mon, 05/06/2024 - 14:19
ECBE
DIAGNÓSTICO, TRATAMIENTO, REHABILITACIÓN Y SEGUIMIENTO DEL PACIENTE CON ESCLEROSIS MÚLTIPLE
seccion ECBE
Referencias
Body
  1. Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S, et al. Multiple sclerosis. Nat Rev Dis Primer. 8 de noviembre de 2018;4(1):1-27.
  2. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler Houndmills Basingstoke Engl. diciembre de 2020;26(14):1816-21.
  3. Guía de Práctica Clínica sobre la atención a las personas con esclerosis múltiple [Internet]. GuíaSalud. 2019 [citado 8 de enero de 2024]. Disponible en: https://portal.guiasalud.es/gpc/guia-de-practica-clinica-sobre-la-atencion-a-las-personas-con-esclerosis-multiple/
  4. Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. agosto de 2021;20(8):653-70.
  5. De Silvestri A, Capittini C, Mallucci G, Bergamaschi R, Rebuffi C, Pasi A, et al. The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Dis Markers. 6 de noviembre de 2019;2019:e1409069.
  6. Rojas OL, Rojas-Villarraga A, Cruz-Tapias P, Sánchez JL, Suárez-Escudero JC, Patarroyo MA, et al. HLA class II polymorphism in Latin American patients with multiple sclerosis. Autoimmun Rev. 1 de abril de 2010;9(6):407-13.
  7. Baranzini Lab [Internet]. [citado 10 de marzo de 2024]. Class II HLA interactions modulate genetic risk for multiple sclerosis. Disponible en: https://baranzinilab.ucsf.edu/publications/class-ii-hla-interactions-modulate-genetic-risk-multiple-sclerosis
  8. INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 27 de septiembre de 2019;365(6460):eaav7188.
  9. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 21 de enero de 2022;375(6578):296-301.
  10. Xiao D, Ye X, Zhang N, Ou M, Guo C, Zhang B, et al. A meta-analysis of interaction between Epstein-Barr virus and HLA-DRB1*1501 on risk of multiple sclerosis. Sci Rep. 11 de diciembre de 2015;5:18083. 
  11. Vizcarra DR, Cruz AG, Rojas E, Mori N, Caparó C, Castañeda CC, et al. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Esclerosis Múltiple en Adultos. Rev Neuro-Psiquiatr. 20 de diciembre de 2019;82(4):242-57.
  12. Leocani L, Guerrieri S, Comi G. Visual Evoked Potentials as a Biomarker in Multiple Sclerosis and Associated Optic Neuritis. J Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc. septiembre de 2018;38(3):350-7.
  13. Britze J, Frederiksen JL. Optical coherence tomography in multiple sclerosis. Eye. mayo de 2018;32(5):884-8.
  14. Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler Houndmills Basingstoke Engl. julio de 2017;23(8):1123-36.
  15. Overview | Multiple sclerosis in adults: management | Guidance | NICE [Internet]. NICE; 2022 [citado 26 de septiembre de 2023]. Disponible en: https://www.nice.org.uk/guidance/ng220
  16. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 1 de febrero de 2018;17(2):162-73.
  17. Brouwers MC, Kerkvliet K, Spithoff K, AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 8 de marzo de 2016;i1152.
  18. Engel S, Zipp F. Preventing disease progression in multiple sclerosis—insights from large real-world cohorts. Genome Med. 20 de abril de 2022;14(1):41.
  19. Slater RJ, LaRocca NG, Scheinberg LC. Development and testing of a minimal record of disability in multiple sclerosis. Ann N Y Acad Sci. 1984;436:453-68.
  20. Recommendations | End of life care for adults: service delivery | Guidance | NICE [Internet]. NICE; 2019 [citado 8 de enero de 2024]. Disponible en: https://www.nice.org.uk/guidance/ng142/chapter/Recommendations#identifying-adults-who-may-be-approaching-the-end-of-their-life-their-carers-and-other-people
  21. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis | Neurology [Internet]. 2023 [citado 26 de septiembre de 2023]. Disponible en: https://n.neurology.org/content/90/17/777
  22. Kaunzner UW, Al-Kawaz M, Gauthier SA. Defining Disease Activity and Response to Therapy in MS. Curr Treat Options Neurol. mayo de 2017;19(5):20.
  23. Díaz C, Zarco LA, Rivera DM. Highly active multiple sclerosis: An update. Mult Scler Relat Disord. 1 de mayo de 2019;30:215-24.
  24. ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis - Xavier Montalban, Ralf Gold, Alan J Thompson, Susana Otero-Romero, Maria Pia Amato, Dhia Chandraratna, Michel Clanet, Giancarlo Comi, Tobias Derfuss, Franz Fazekas, Hans Peter Hartung, Eva Havrdova, Bernhard Hemmer, Ludwig Kappos, Roland Liblau, Catherine Lubetzki, Elena Marcus, David H Miller, Tomas Olsson, Steve Pilling, Krysztof Selmaj, Aksel Siva, Per Soelberg Sorensen, Maria Pia Sormani, Christoph Thalheim, Heinz Wiendl, Frauke Zipp, 2018 [Internet]. 2024 [citado 3 de febrero de 2024]. Disponible en: https://journals.sagepub.com/doi/10.1177/1352458517751049
  25. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis | CNS Drugs [Internet]. 2024 [citado 8 de enero de 2024]. Disponible en: https://link.springer.com/article/10.1007/s40263-022-00965-7
  26. https://fyra.io. Practical Neurology. Bryn Mawr Communications; 2024 [citado 8 de enero de 2024]. De-Escalation from High- or Moderate-Efficacy to Low-Efficacy Disease Modifying Therapy in Patients with Multiple Sclerosis Shown to be Safe According to New Research. Disponible en: https://practicalneurology.com/news/de-escalation-from-high-or-moderate-efficacy-to-low-efficacy-disease-modifying-therapy-in-patients-with-multiple-sclerosis-shown-to-be-safe-according-to-new-research
  27. Köpke S, Solari A, Khan F, Heesen C, Giordano A. Information provision for people with multiple sclerosis. Cochrane Database Syst Rev [Internet]. 2014 [citado 8 de marzo de 2024];(4). Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008757.pub2/full
  28. Ramo-Tello C, Blanco Y, Brieva L, Casanova B, Martínez-Cáceres E, Ontaneda D, et al. Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses. J Pers Med. 22 de diciembre de 2021;12(1):6.
  29. Ilott I, Rick J, Patterson M, Turgoose C, Lacey A. What is protocol-based care? A concept analysis. J Nurs Manag. 2006;14(7):544-52.
  30. Gulwani S. Programming by Examples: Applications, Algorithms, and Ambiguity Resolution.
  31. Jun GT, Ward J, Morris Z, Clarkson J. Health care process modelling: which method when? Int J Qual Health Care. 1 de junio de 2009;21(3):214-24.
  32. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 29 de marzo de 2021;372:n71.
  33. MS Counseling Points Winter 2016 [Internet]. [citado 10 de marzo de 2024]. Disponible en: http://digitaledition.qwinc.com/publication/?i=292267&view=issueViewer&pp=1